Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Next Previous
X
Search
Trial Profile

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Anal cancer; Carcinoma; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOBLET

    • Most Recent Events

    • 01 Aug 2024 According to an Oncolytics Biotech media release, mFOLFIRINOX cohort safety run-in update expected in H1 2025.
    • 20 Jun 2024 According to an Oncolytics Biotech media release, first patient dosed in fifth cohort. The fifth cohort It will be conducted in collaboration with AIO-Studien-gGmbH (AIO), a clinical trial group within the German Cancer Society, as part of GOBLET.
    • 04 Jun 2024 Trial design evaluating pelareorep plus modified FOLFIRINOX with or without the PD-L1 inhibitor atezolizumab as first-line therapy in patients with mPDAC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top